江西三鑫医疗科技股份有限公司 2022 年第三季度报告 证券代码：300453 证券简称：三鑫医疗 公告编号：2022-052 江西三鑫医疗科技股份有限公司 2022年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 324,351,752.18 | 2.17% | 984,555,678.59 | 19.13% | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥660,203,926.41, representing a 29.71% increase compared to ¥508,993,232.09 in the same period last year[24]. - The net profit attributable to shareholders for the first half of 2022 was ¥104,736,931.56, a 47.17% increase from ¥71,169,206.67 in the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,496,899.72, up 48.15% from ¥66,485,208.09 in the same period last year[24]. - The net cash flow from operating activities was ¥87,312,813.69, an increase of 8.16% compared to ¥80,722,586.52 in the previous year[24]. - The total assets at the end of the reporting period were ¥1,587,298,006.53, reflecting a 12.89% increase from ¥1,406,039,522.12 at the end of the previous year[24]. - The net assets attributable to shareholders at the end of the reporting period were ¥965,556,400.66, a 6.63% increase from ¥905,506,389.18 at the end of the previous year[24]. - The basic earnings per share for the first half of 2022 were ¥0.2658, up 47.18% from ¥0.1806 in the same period last year[24]. - The diluted earnings per share for the first half of 2022 were also ¥0.2658, reflecting a 47.18% increase compared to ¥0.1806 in the previous year[24]. - The weighted average return on equity was 12.77%, an increase of 3.91% from 8.86% in the previous year[24]. Product Development and Market Position - The company has transformed from traditional infusion products to a leading provider of comprehensive blood purification solutions, covering five major product series: blood purification, injection, indwelling catheter, infusion and blood transfusion, and thoracic surgery[32]. - The company has established a nationwide production layout for blood purification, with its subsidiary Chengdu Weili Sheng recognized as a leading provider of blood dialysis equipment in China[35]. - The company has developed a second production line for hollow fiber blood dialysis membranes, which is expected to enhance production capacity and improve product efficiency[36]. - The company holds a high market share in blood dialysis concentrates and has automated its production line from input to packaging[36]. - The company actively participates in the formulation and revision of national and industry standards, having completed 2 national standards and 3 industry standards[37]. - The company aims to be a top manufacturer in the medical consumables sector and is focused on developing new products to enhance its market position[38]. - The company has established itself as an operator in the blood purification industry, focusing on products for end-stage renal disease (ESRD) patients[40]. - The core product of the blood purification segment is the hemodialyzer, which utilizes hollow fiber membrane technology for effective blood treatment[43]. - The company’s hemodialysis machine (model W-T2008-B) and hemodialysis filter machine (model W-T6008S) are designed for adult chronic kidney failure patients, ensuring precise control of treatment parameters[43]. - The market share of the company's dialysis solution products ranks among the top in the domestic market[43]. - The company has an annual production capacity of over 2,000 sets for dialysis tubing[43]. - The hemodialysis products are essential for both acute and chronic kidney failure patients, providing necessary electrolytes and correcting acid-base imbalances during treatment[43]. - The company is committed to continuous innovation and development in the blood purification product line to meet diverse patient needs[40]. - The company’s products are designed to ensure safety and efficiency in clinical settings, with a focus on enhancing patient care[45]. Revenue Breakdown - Blood purification products generated revenue of 404.49 million yuan, accounting for 61.27% of total revenue, with a growth of 20.71% compared to the previous year[56]. - Injection products saw revenue of 134.09 million yuan, representing a significant increase of 94.67%, with vaccine syringe sales reaching 359 million units, up 240% year-on-year[56]. - The company reported a 31.02% increase in revenue from infusion and blood transfusion products, totaling 39.21 million yuan, which accounted for 5.94% of total revenue[57]. Research and Development - The company invested CNY 29.54 million in R&D during the reporting period, accounting for 4.47% of its revenue, with a year-on-year increase of 27.87%[73]. - The company holds 111 authorized patents and has 62 patents under application, along with 86 registered medical device certificates[73]. - The company has a strong R&D team and capabilities, having established several research centers and participated in the formulation of 2 national standards and 8 industry standards[78]. Strategic Initiatives - The company is actively exploring market expansion opportunities to strengthen its position in the healthcare sector[40]. - The company aims to enhance operational efficiency through strategic partnerships and technological advancements in its product offerings[40]. - The company formed a high-performance medical device industry innovation consortium in Jiangxi Province, collaborating with 13 research institutions and 23 industry representatives to drive technological advancements[59]. Environmental and Social Responsibility - The company has established a wastewater management system based on the principle of "rainwater and sewage diversion," ensuring that domestic wastewater is pre-treated before being sent to the park's sewage treatment plant for further processing[113]. - The company has implemented measures to reduce carbon emissions, including the use of advanced production processes and energy-saving equipment, which have led to a decrease in energy consumption and carbon emissions[113]. - The company actively engages in social responsibility initiatives, including donations of medical supplies during the COVID-19 pandemic and support for local employment and rural revitalization[117]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[8]. - The company appointed a new deputy general manager, Leng Lingli, on March 15, 2022[107]. - The company has implemented a restricted stock incentive plan, granting 8.5 million shares at a price of 6.43 CNY per share to 93 eligible participants[109]. - The company’s major shareholders, including Peng Yixing and Lei Fenglian, committed to not reducing their shareholdings within three years post-IPO[120]. - The company reported that there were no non-operating fund occupations by controlling shareholders or other related parties during the reporting period[123]. - There were no violations of external guarantees during the reporting period[124]. - The company has not experienced any bankruptcy reorganization matters during the reporting period[126]. Risks and Challenges - The company faces risks related to national policy changes that could impact the competitive landscape of the medical device industry[102]. - Quality control risks are significant due to the nature of the company's products being classified as Class III medical devices, which are subject to strict regulatory scrutiny[102]. - Rising raw material prices pose a risk to profit margins, influenced by the complex international political and economic environment[102].

Financial Performance - The company's revenue for Q1 2022 was CNY 321,497,637.25, representing a 30.61% increase compared to CNY 246,148,032.60 in the same period last year[4] - Net profit attributable to shareholders was CNY 47,447,455.87, up 39.37% from CNY 34,044,129.84 year-on-year[4] - Basic earnings per share rose to CNY 0.1204, a 39.35% increase from CNY 0.0864 in the same period last year[4] - Total operating revenue for Q1 2022 reached ¥321,497,637.25, an increase of 30.6% compared to ¥246,148,032.60 in Q1 2021[20] - Net profit for Q1 2022 was ¥50,359,581.15, representing a 34.5% increase from ¥37,411,131.05 in Q1 2021[21] - Earnings per share for Q1 2022 were ¥0.1204, compared to ¥0.0864 in Q1 2021, reflecting a growth of 39.3%[22] Cash Flow - The net cash flow from operating activities increased by 127.00%, reaching CNY 14,868,783.06 compared to CNY 6,550,259.90 in the previous year[4] - Cash flow from operating activities in Q1 2022 was ¥350,610,682.58, an increase of 32.6% from ¥264,314,438.96 in Q1 2021[23] - The net cash flow from operating activities for Q1 2022 was ¥14,868,783.06, an increase from ¥6,550,259.90 in Q1 2021, representing a growth of approximately 127%[24] - The total cash outflow from operating activities was ¥335,741,899.52, compared to ¥257,764,179.06 in the previous year, reflecting an increase of approximately 30%[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,442,878,734.42, reflecting a 2.62% increase from CNY 1,406,039,522.12 at the end of the previous year[4] - The total liabilities decreased from CNY 379,357,648.27 to CNY 353,107,022.77, a reduction of approximately 6.9%[17] - Current assets amounted to CNY 588,432,679.18, up from CNY 548,228,432.28 at the start of the year, indicating an increase of about 7.3%[16] - The company’s long-term assets totaled CNY 854,446,055.24, slightly down from CNY 857,811,089.84 at the beginning of the year[17] - Total liabilities as of Q1 2022 were ¥406,477,102.44, a decrease from ¥427,244,790.66 in the previous year[21] Equity - The company's equity attributable to shareholders increased by 6.01%, amounting to CNY 959,968,858.03 compared to CNY 905,506,389.18 at the end of the last year[4] - Total equity attributable to shareholders of the parent company was ¥959,968,858.03, an increase of 6.0% from ¥905,506,389.18 in Q1 2021[21] Expenses - Research and development expenses increased by 72.34% to CNY 9,481,656.95, driven by increased investment in R&D projects[8] - Management expenses rose significantly by 98.56% to CNY 25,646,319.89, primarily due to increased stock incentive expenses[8] - Research and development expenses for Q1 2022 amounted to ¥9,481,656.95, up 72.5% from ¥5,501,825.94 in Q1 2021, indicating a strong focus on innovation[21] Market Strategy - The company plans to continue expanding its market presence in blood purification products, which have shown sustained revenue growth[8] - The company plans to invest CNY 568 million in a new research and production base for blood dialysis products, which is expected to enhance production capacity and support future business expansion[14] Sales Performance - The company reported a significant increase in sales collection, contributing to the rise in operating cash flow[8] - The company reported cash received from sales, totaling ¥332,918,108.44 in Q1 2022, compared to ¥250,206,117.69 in Q1 2021, reflecting strong sales performance[23]

Financial Performance - The company's operating revenue for 2021 was ¥1,164,288,763.57, representing a 23.81% increase compared to ¥940,385,589.06 in 2020[24]. - The net profit attributable to shareholders for 2021 was ¥155,910,663.53, a 34.84% increase from ¥115,624,846.75 in 2020[24]. - The net profit after deducting non-recurring gains and losses was ¥145,190,265.25, up 43.68% from ¥101,050,763.98 in 2020[24]. - The company's cash flow from operating activities for 2021 was ¥329,716,957.18, a 20.82% increase from ¥272,895,487.24 in 2020[24]. - The total assets at the end of 2021 were ¥1,406,039,522.12, reflecting a 12.96% increase from ¥1,244,754,307.25 at the end of 2020[24]. - The net assets attributable to shareholders at the end of 2021 were ¥905,506,389.18, a 15.32% increase from ¥785,198,391.69 at the end of 2020[24]. - The company achieved operating revenue of CNY 1,164.29 million, a year-on-year increase of 23.81%[90]. - Net profit attributable to shareholders reached CNY 155.91 million, up 34.84% compared to the previous year[82]. - The total revenue for 2021 was approximately CNY 1.28 billion, representing an increase of 18.22% compared to CNY 1.08 billion in 2020[105]. Dividend Distribution - The company plans to distribute a cash dividend of 1.50 RMB per 10 shares to all shareholders, based on a total of 394,027,500 shares[9]. - The company distributed a cash dividend of RMB 2.00 per 10 shares, totaling RMB 52,537,000, and issued 1.5 bonus shares per 10 shares, along with a capital increase of 3.5 shares per 10 shares, increasing the total share capital to 394,027,500 shares[161]. - The total distributable profit for the year was RMB 416,784,890.37, with the cash dividend accounting for 100% of the profit distribution[163]. - The company's cash dividend policy complies with the company's articles of association and provides clear standards and procedures for distribution[162]. Market Position and Strategy - The company is focused on expanding its market presence and developing new products and technologies to enhance competitiveness[6]. - The company has established several wholly-owned and controlling subsidiaries to enhance its operational capabilities and market reach[17]. - The company has been recognized as a leading enterprise in the blood purification industry, providing a full range of products including dialysis machines and related consumables[40]. - The company aims to expand its market presence through strategic initiatives and product innovation in the medical device sector[47]. - The company has a strong brand presence in the blood purification market, with its products gaining recognition and trust among customers[81]. - The company plans to continue expanding its market share in blood purification products and enhance its product structure through new developments[85]. Research and Development - The company has a strong R&D team and capabilities, having established multiple research centers and contributed to the formulation of 2 national standards and 8 industry standards[78]. - The company’s R&D investment for 2021 was CNY 61.19 million, accounting for 5.26% of total revenue, representing a year-on-year increase of 30.29%[102]. - The number of R&D personnel increased to 247 in 2021, up 9.78% from 225 in 2020, with R&D personnel now making up 13.15% of the total workforce[102]. - The company is focused on reducing the economic burden on patients by promoting domestic alternatives to imported products[102]. - The company aims to enhance its core competitiveness and market expansion capabilities through the development of new products[102]. Regulatory and Compliance - The company operates in a highly regulated medical device industry, which is subject to strict national policies and quality control standards[6][7]. - The company has received various certifications, including CE and FDA510(k), ensuring compliance with international quality standards[79]. - The company has implemented a transparent performance evaluation and incentive mechanism for senior management[130]. - The company has established and optimized internal control systems in accordance with the latest regulations, ensuring effective governance and decision-making processes[171]. - There were no significant internal control deficiencies identified during the reporting period, with all financial and non-financial reporting controls deemed effective[172]. Corporate Governance - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team[124]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[126]. - The company maintains independence from its controlling shareholders in terms of business, personnel, assets, and finance[132]. - The company actively engages with shareholders through various communication channels to ensure their rights are protected[125]. - The company’s board has been proactive in enhancing the operational standards and protecting the rights of minority shareholders[152]. Social Responsibility and Sustainability - The company has actively engaged in social responsibility initiatives, emphasizing employee welfare and contributions to health advancements[181]. - The company has implemented measures to reduce carbon emissions, including the use of clean energy sources and optimizing production locations to minimize transportation emissions[180]. - The company was recognized as a "2021 Occupational Health Demonstration Enterprise" in Nanchang, reflecting its commitment to workplace safety and health[179]. - The company actively creates job opportunities to support rural employment and talent development[184]. - The company has implemented a procurement management system to maintain a win-win situation with suppliers[183]. Product Development and Innovation - The company has continuously optimized its product structure, transitioning from traditional infusion to a comprehensive range of medical devices across six major segments[33]. - The company has established a complete industrial chain from blood purification consumables to equipment, positioning itself as a leader in the industry[35]. - The company reported a significant focus on the development of single-use sterile injection devices, which are designed to minimize injection pain for insulin administration[57]. - The introduction of a closed intravenous catheter system allows for a needle-free connection, reducing the workload for healthcare professionals[59]. - The company is expanding its product line to include light-protective infusion devices, which are essential for administering light-sensitive medications[63].

Financial Performance - The company's revenue for Q3 2021 reached ¥317,476,887.58, representing a 29.40% increase compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥43,331,185.29, up 15.33% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥38,926,344.26, reflecting a 29.19% increase compared to the previous year[4] - Total operating revenue for Q3 2021 reached ¥826,470,119.67, an increase of 20.5% compared to ¥681,997,820.49 in the same period last year[25] - Operating profit for Q3 2021 was ¥149,963,191.98, up 34.7% from ¥111,249,387.48 in Q3 2020[26] - Net profit for Q3 2021 was ¥126,824,272.64, representing a 40.9% increase from ¥89,990,501.62 in Q3 2020[26] - Basic and diluted earnings per share for Q3 2021 were both ¥0.2906, compared to ¥0.2083 in the same quarter last year, reflecting a 39.4% increase[27] - The company reported a total comprehensive income of ¥126,824,272.64 for Q3 2021, compared to ¥89,990,501.62 in Q3 2020, an increase of 40.9%[27] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥1,311,151,511.94, a 5.33% increase from the end of the previous year[4] - Total assets as of Q3 2021 amounted to ¥1,311,151,511.94, up from ¥1,244,754,307.25 at the end of Q3 2020, marking a growth of 5.3%[23] - Total liabilities decreased to ¥392,213,208.85 in Q3 2021 from ¥399,519,382.95 in Q3 2020, a reduction of 1.8%[23] - The company's non-current assets totaled ¥813,294,159.05, an increase of 5.8% from ¥768,903,358.53 in the previous year[23] Cash Flow - Cash flow from operating activities for the year-to-date was ¥202,443,690.56, showing an 18.88% increase[4] - Operating cash inflow for the current period reached ¥890,964,419.65, an increase of 5.4% compared to ¥845,491,338.30 in the previous period[28] - Net cash flow from operating activities was ¥202,443,690.56, up 18.9% from ¥170,292,205.53 in the prior year[30] - Total cash outflow from operating activities was ¥688,520,729.09, compared to ¥675,199,132.77 in the previous period[30] - Cash inflow from investment activities totaled ¥466,712,451.95, down 13.5% from ¥539,457,765.52 in the previous period[30] - Net cash flow from investment activities was -¥27,901,018.83, an improvement from -¥174,006,239.84 in the prior year[30] - Cash inflow from financing activities was ¥101,600,002.00, down 32% from ¥149,358,730.95 in the previous period[30] - Net cash flow from financing activities was -¥115,070,420.90, worsening from -¥50,694,224.38 in the previous year[30] - The ending balance of cash and cash equivalents was ¥150,857,709.39, significantly up from ¥49,812,723.41 in the previous period[30] Equity and Shareholder Information - The weighted average return on equity for the year-to-date was 14.08%, an increase of 1.02% compared to the previous year[4] - The company’s basic earnings per share for Q3 2021 was ¥0.1100, a 15.30% increase year-on-year[4] - The total equity attributable to shareholders increased to ¥849,379,974.98, an 8.17% rise from the previous year-end[4] - The company approved a restricted stock incentive plan to issue up to 8.5 million shares at a price of CNY 6.43 per share, representing 2.16% of the total share capital[18] - The total estimated expense for the restricted stock incentive plan from 2021 to 2024 is projected to be CNY 56.62 million[19] Current Assets and Inventory - As of September 30, 2021, the company's total current assets amounted to CNY 497,857,352.89, an increase from CNY 475,850,948.72 at the end of 2020, representing a growth of approximately 4.2%[21] - Cash and cash equivalents increased to CNY 175,539,659.39 from CNY 98,264,811.59, showing a significant rise of approximately 78.5%[21] - Accounts receivable rose to CNY 105,423,215.44 from CNY 93,967,507.50, reflecting an increase of about 12.2%[21] - Inventory levels were reported at CNY 148,509,654.86, slightly up from CNY 143,316,557.53, indicating a growth of approximately 3.0%[21] - The company’s fixed assets increased to CNY 483,449,080.05 from CNY 467,012,829.99, marking a growth of approximately 3.5%[21] - Long-term receivables decreased slightly to CNY 5,477,431.62 from CNY 5,768,103.91, a decline of about 5.0%[21] - The company’s total non-current assets include CNY 10,000,000.00 in debt investments, unchanged from the previous period[21] Research and Development - Research and development expenses for Q3 2021 were ¥23,334,153.88, up 28.0% from ¥18,267,008.25 in Q3 2020, indicating a focus on innovation[26] Government Subsidies - The company received government subsidies amounting to ¥7,451,194.42 during the reporting period[5] Employee Compensation - Employee compensation payments increased to ¥139,007,908.95, up 27.5% from ¥109,051,774.28 in the previous period[28] Deferred Income - Deferred income increased to ¥35,813,500.20 from ¥23,742,502.81, reflecting a growth of 50.8% year-over-year[23]

Financial Performance - The company achieved operating revenue of ¥508,993,232.09, representing a year-on-year increase of 16.57%[24]. - Net profit attributable to shareholders reached ¥71,169,206.67, marking a significant growth of 59.98% compared to the same period last year[24]. - The net profit after deducting non-recurring gains and losses was ¥66,485,208.08, an increase of 51.47% year-on-year[24]. - The company reported a basic earnings per share of ¥0.1806, up 59.96% from the previous year[24]. - The company's operating income for the first half of 2021 was CNY 424,762,830.43, an increase of 13.09% compared to CNY 375,625,539.02 in the same period of 2020[178]. - Net profit for the first half of 2021 reached CNY 79,169,132.27, representing a 61.41% increase from CNY 49,074,222.19 in the first half of 2020[175]. - The total profit for the first half of 2021 was CNY 90,851,165.40, an increase of 54.67% compared to CNY 58,739,988.92 in the first half of 2020[175]. Share Capital and Dividends - The company reported a total increase in share capital of 131,342,500 shares due to a rights distribution, resulting in a change in basic and diluted earnings per share from RMB 0.1693 to RMB 0.1129[23]. - The company does not plan to distribute cash dividends or issue bonus shares[9]. - The company completed a rights distribution on April 29, 2021, distributing 1.5 shares for every 10 shares held and increasing the total share capital by 131,342,500 shares, resulting in a new total of 394,027,500 shares[143]. - The cash dividend distributed was RMB 2.00 per share, totaling RMB 52,537,000 (including tax) based on the total share capital of 262,685,000 shares as of December 31, 2020[143]. Market and Industry Context - The company operates in a highly regulated medical device industry, which is subject to significant national policy risks that could impact its operations[5]. - The ongoing reform of the medical insurance system aims to optimize the medical insurance catalog, which will include high-value clinical products, enhancing market access for the company's offerings[58]. - The domestic substitution of high-end medical devices is accelerating, with increased reimbursement rates for domestic products, enhancing their competitiveness in the market[60]. - The demand for medical devices in county-level hospitals is expected to rise significantly due to government initiatives to improve healthcare capabilities[61]. - The aging population and rising chronic diseases are projected to increase the number of end-stage renal disease patients in China to over 4 million by 2030[63]. - The Chinese medical device market has grown by nearly 400 billion RMB from 2014 to 2019, with an average annual growth rate of around 20%, significantly outpacing the global market[65]. Product Development and Innovation - The company focuses on continuous product development and has transitioned to providing comprehensive blood purification solutions[31]. - The company is expanding its market presence by enhancing product offerings in the injection and dialysis segments, responding to increased demand due to public health initiatives[38]. - The company’s innovative product features, such as the closed design of intravenous catheters, improve clinical safety and reduce the workload for healthcare professionals[41]. - The company is committed to meeting diverse clinical needs with a wide range of product specifications and designs in its injection product line[39]. - The company invested 23.1 million RMB in R&D, accounting for 4.54% of its revenue, and holds 73 authorized patents, indicating a strong commitment to innovation[68]. - The company is currently applying for 8 new medical device registrations, reflecting its ongoing efforts to expand its product portfolio[68]. Quality Control and Compliance - The company faces quality control risks as its main products are classified as Class III medical devices, which require strict adherence to safety and effectiveness standards[6]. - The company emphasizes the importance of maintaining effective quality management systems to avoid reputational damage and operational impacts[7]. - The company has a well-established quality management system, having obtained certifications from the EU CE and CMD, as well as FDA510(k) approval for some products[74]. - The company is focused on maintaining quality control to mitigate risks associated with its medical device products[102]. Financial Position and Assets - The total assets at the end of the reporting period were ¥1,233,157,081.49, a decrease of 0.93% from the end of the previous year[24]. - The net assets attributable to shareholders increased to ¥805,495,295.31, representing a growth of 2.58% compared to the end of the previous year[24]. - The company's cash and cash equivalents increased by 151.29% to ¥22,518,145.89, compared to a negative balance of ¥43,901,856.85 in the previous year[79]. - The company's total assets as of June 30, 2021, were CNY 1,099,983,355.17, a slight decrease from CNY 1,110,491,235.69 at the end of 2020[171]. - Total liabilities decreased to CNY 319,478,717.23 from CNY 337,867,985.97, indicating a reduction of 5.5%[172]. Corporate Governance and Shareholder Information - The company’s financial report has been confirmed as true, accurate, and complete by its board of directors and management[3]. - The total number of shareholders at the end of the reporting period is 22,632[149]. - 彭义兴 holds 24.79% of the shares, totaling 97,673,880 shares, with an increase of 32,557,960 shares during the reporting period[150]. - The company has a commitment that 75% of the shares held by directors and senior management will be locked during their tenure[146]. Social Responsibility and Community Engagement - The company actively participates in social responsibility initiatives, including creating job opportunities and supporting pandemic relief efforts[117].

Financial Performance - The company's operating revenue for Q1 2021 was CNY 246,148,032.60, representing a 42.82% increase compared to CNY 172,344,526.82 in the same period last year[8]. - Net profit attributable to shareholders was CNY 34,044,129.84, a significant increase of 180.35% from CNY 12,143,542.89 year-on-year[8]. - The net profit after deducting non-recurring gains and losses reached CNY 30,524,795.18, up 216.62% from CNY 9,640,940.93 in the previous year[8]. - Basic earnings per share increased to CNY 0.13, reflecting a growth of 160.00% compared to CNY 0.05 in the same quarter last year[8]. - The weighted average return on net assets improved to 4.24%, up 2.26% from 1.98% in the previous year[8]. - The company's operating revenue for the reporting period reached CNY 246.15 million, a 42.82% increase compared to CNY 172.34 million in the same period last year, driven by enhanced market expansion efforts[21]. - The net profit attributable to shareholders was CNY 34.04 million, reflecting a significant growth of 180.35% year-over-year, primarily due to increased sales and improved gross margins in blood purification products[22]. - The total profit for Q1 2021 was CNY 43,879,641.07, a 166.67% increase from CNY 16,489,282.87 in Q1 2020[42]. Cash Flow and Assets - The net cash flow from operating activities was CNY 6,550,259.90, down 70.94% from CNY 22,537,655.83 in the same period last year[8]. - Cash inflows from operating activities totaled CNY 264,314,438.96, an increase from CNY 231,595,387.86 in Q1 2020, demonstrating robust cash generation[48]. - The cash inflow from investment activities was 244,756,751.40 CNY, a significant increase from 80,268,179.83 CNY in the previous period[53]. - The total cash and cash equivalents at the end of the period were 98,066,217.25 CNY, an increase from 37,979,679.35 CNY in the previous period[50]. - Cash and cash equivalents decreased to CNY 44,464,420.66 from CNY 61,262,685.77, a decline of 27.3%[36]. - The company reported a significant increase in prepayments, which rose by 87.64% to CNY 43.88 million, reflecting higher advance payments for equipment[21]. - Short-term borrowings decreased by 58.82% to CNY 46.43 million, as the company repaid loans during the reporting period[21]. Shareholder and Executive Compensation - The total number of ordinary shareholders at the end of the reporting period was 26,070[12]. - The company reported a total of 48,836,940 restricted shares held by 彭义兴, which remain locked during the tenure of the executive[15]. - 雷凤莲 holds 9,930,960 restricted shares, also locked for the duration of the executive's term[15]. - The total number of restricted shares for 王兰 is 2,977,897, with a 75% lock-up during the executive's term[15]. - The company has a performance-based unlocking mechanism for restricted shares, with specific shares set to be released in 2021 based on performance evaluations[16]. - The company has a consistent policy of locking 75% of shares for executives during their tenure, ensuring alignment with shareholder interests[15]. - The performance evaluation for unlocking shares will be conducted annually, ensuring accountability and performance alignment[16]. Research and Development - Research and development expenses increased by 40.58% to CNY 5.50 million, indicating a commitment to enhancing product innovation[21]. - Research and development expenses increased to CNY 5,501,825.94, up 40.67% from CNY 3,913,570.35, highlighting the company's commitment to innovation[45]. Market and Operational Risks - The company faces risks related to national policy changes, quality control, and market contraction in traditional infusion products, which may impact future operations[23]. - The company is focused on becoming a leading manufacturer in the medical consumables sector while expanding its blood purification industry platform[22]. Stock Incentive Plans - The company is actively managing its stock incentive plans to align employee performance with company goals[19]. - The report highlights a significant focus on performance evaluation for stock unlocks, which may impact future employee motivation and retention[18]. - The company is committed to transparency in its stock incentive programs, as evidenced by detailed disclosures in the report[19]. - The overall strategy includes leveraging stock options to enhance employee engagement and align interests with shareholders[19].

Financial Performance - The company's operating revenue for 2020 was CNY 940,385,589.06, representing a 30.31% increase compared to CNY 721,668,064.47 in 2019[17]. - The net profit attributable to shareholders for 2020 was CNY 115,624,846.75, an increase of 87.45% from CNY 61,683,106.48 in 2019[17]. - The net profit after deducting non-recurring gains and losses was CNY 101,050,763.98, up 87.54% from CNY 53,881,499.47 in 2019[17]. - The net cash flow from operating activities reached CNY 272,895,487.24, a 63.06% increase from CNY 167,355,013.58 in 2019[17]. - The total assets at the end of 2020 were CNY 1,244,754,307.25, an 8.65% increase from CNY 1,145,700,357.46 at the end of 2019[17]. - The net assets attributable to shareholders increased by 17.34% to CNY 785,198,391.69 from CNY 669,151,400.74 in 2019[17]. - The company reported a basic earnings per share of CNY 0.45, up 87.50% from CNY 0.24 in 2019[17]. - The company achieved operating revenue of 940.39 million yuan, a year-on-year increase of 30.31%[67]. - The operating profit reached 155.17 million yuan, growing by 100.18% compared to the previous year[67]. - Blood purification products generated sales revenue of 583.15 million yuan, up 29.51% year-on-year, accounting for 62.01% of total revenue[70]. Dividend Distribution - The company plans to distribute a cash dividend of 2 RMB (including tax) for every 10 shares, along with a bonus share of 1.5 shares and a capital reserve increase of 3.5 shares for every 10 shares[9]. - The cash dividend for 2020 represents 45.44% of the net profit attributable to ordinary shareholders[127]. - The company reported a total of 262,685,000 shares as of December 31, 2020, for the dividend calculation[126]. - The cash dividend for 2019 was RMB 1.00 per 10 shares, totaling RMB 26,270,500, which was 42.59% of the net profit[127]. - The company has maintained a consistent dividend distribution policy over the past three years, with increasing amounts each year[126]. - The company's profit distribution plan for 2020 is subject to approval at the annual shareholders' meeting[125]. Market and Industry Context - The company operates in a highly regulated medical device industry, which is subject to strict national policies and quality control standards[5][6]. - The market for traditional infusion products is experiencing a decline due to national medical reforms and policies limiting the use of antibiotics[8]. - The company acknowledges the potential impact of changes in national regulatory policies on its operational landscape[5]. - The demand for medical devices in grassroots healthcare institutions is expected to increase due to the promotion of hierarchical diagnosis and treatment[53]. - The number of dialysis patients in China was 633,000 in 2019, with projections indicating it will exceed 4 million by 2030[54]. Product Development and Innovation - The company is focused on expanding its market presence and developing new products and technologies in the medical device sector[4]. - The company has expanded its product offerings to include six major categories, including blood purification and protective products, in response to market needs[27]. - The company is actively promoting the import substitution of dialysis machines, aiming to capture a larger share of the domestic market[31]. - The company aims to expand its market presence by introducing new products, including a disposable blood micro-embolism filter that maximizes blood flow while minimizing damage[43]. - The annual report indicates a commitment to innovation in medical technology, with ongoing research into new product development and enhancements in existing offerings[37]. Operational Efficiency and Management - The company faces risks related to business integration and management efficiency as it expands through mergers and acquisitions[9]. - The company emphasizes the importance of maintaining effective quality management systems to avoid potential reputational damage and operational impacts[6][7]. - The company has established a nationwide production and manufacturing base with subsidiaries in multiple provinces, enhancing its operational footprint[27]. - The company reported a significant increase in profitability from its subsidiary Yunnan Sanxin, which improved production management efficiency and cost control[114]. Regulatory Compliance and Governance - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management[3]. - The company has participated in the formulation or revision of 2 national standards and 3 industry standards, enhancing its industry status[57]. - The company has adhered to all commitments made by its shareholders during the reporting period, with no violations reported[128]. - The company has no significant related party transactions during the reporting period[154]. Research and Development - Research and development investment totaled 46.97 million yuan, representing 4.99% of operating revenue for the reporting period[75]. - R&D personnel accounted for 12.78% of the total workforce, with 225 R&D staff members[93]. - The capitalized amount of R&D expenses was ¥17,474,364.58, representing 37.21% of total R&D investment[93]. - The company plans to strengthen its innovation capabilities and establish a research-driven development model, emphasizing product quality control[117]. Shareholder and Equity Management - The company’s major shareholders, including controlling shareholders Peng Yixing and Lei Fenglian, committed to not reducing their holdings for three years post-IPO[128]. - The company’s shareholders are required to announce any share reductions three trading days in advance[129]. - The company has committed to repurchasing shares if any false statements or omissions are found in the prospectus that materially affect the judgment of compliance with issuance conditions[129]. - The company has a total of 30,575 common shareholders at the end of the reporting period[188]. Social Responsibility - The company is committed to fulfilling social responsibilities by ensuring the availability of essential medical supplies during the pandemic[29]. - The company donated over RMB 2.09 million and provided over RMB 800,000 worth of protective materials during the pandemic[167].

Financial Performance - Net profit attributable to shareholders increased by 64.48% to CNY 37,572,085.88 for the reporting period[7] - Operating income rose by 27.31% to CNY 245,346,868.95 for the reporting period[7] - Net cash flow from operating activities surged by 69.50% to CNY 66,005,094.90[7] - Basic earnings per share increased by 64.11% to CNY 0.1431 for the reporting period[7] - The weighted average return on equity improved to 5.78%, up from 2.12% in the previous year[7] - The company reported a total net profit of CNY 82,057,070.61 for the year-to-date, reflecting a 105.46% increase compared to the same period last year[7] - The net profit attributable to shareholders for the first nine months was ¥82,057,070.61, representing a 105.46% increase from ¥39,938,693.54 in the previous year[22] - The net profit for Q3 2020 reached CNY 29.90 million, representing a growth of 62.3% from CNY 18.44 million in Q3 2019[52] - The net profit for the year-to-date period was CNY 89.99 million, which is an increase of 116.5% compared to CNY 41.46 million in the previous year[58] - The company reported a total profit of CNY 84,133,130.01, which is an increase of 70.4% from CNY 49,361,105.49 in the same quarter last year[61] Asset and Liability Management - Total assets increased by 3.14% to CNY 1,181,717,112.26 compared to the end of the previous year[7] - The company's total assets as of Q3 2020 were CNY 1,077,473,282.94, a slight increase from CNY 1,060,929,815.26 at the end of the previous quarter[47] - The company's total assets of Jiangxi Sanxin Medical Technology Co., Ltd. amounted to CNY 1,181,717,112.26, an increase from CNY 1,145,700,357.46 at the end of 2019[41][44] - The total current liabilities decreased to CNY 360,411,323.37 from CNY 401,910,887.42, a reduction of about 10.3%[43] - The company's long-term receivables decreased slightly to CNY 4,854,426.26 from CNY 5,356,905.63, a decline of about 9.3%[42] - Total liabilities amounted to CNY 427,676,260.49, remaining stable compared to the previous year[71] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,561[11] - The largest shareholder, Peng Yixing, holds 24.79% of the shares, totaling 65,115,920 shares[11] - The total number of restricted shares at the beginning of the period was 48,836,940 for Peng Yixing, with no shares released during the period, maintaining the same number at the end[14] - The company has a commitment to lock 75% of shares for executives during their tenure, affecting multiple shareholders including Peng Haibo and Wang Lan[14] - The report highlights the importance of maintaining a significant portion of shares under lock-up to align executive interests with company performance[15] Compensation and Incentives - The company granted 56,000 restricted stock units to multiple executives, with a vesting period in 2020 and 2021 based on performance assessments[17] - The vesting of restricted stock units is tied to specific performance criteria, promoting accountability among executives[18] - The company plans to continue its strategy of using stock options as a key component of its compensation package to attract and retain top talent[17] - The company is focusing on retaining talent through stock-based compensation, which is expected to enhance long-term performance and stability[17] Revenue and Cost Management - The company's operating revenue for the first nine months of 2020 reached ¥681,997,820.49, a 41.65% increase compared to ¥481,453,727.42 in the same period of 2019[22] - Operating costs rose by 33.30% to ¥427,245,855.66, primarily due to increased revenue leading to higher cost recognition[22] - The company's total operating costs for the year-to-date period were CNY 582.71 million, up 32.4% from CNY 439.66 million in the same period last year[57] Research and Development - Research and development expenses surged by 115.87% to ¥18,267,008.25, reflecting the company's commitment to enhancing R&D efforts[22] - Research and development expenses increased to CNY 6,497,783.76, up 72.0% from CNY 3,776,115.99 in the same period last year, highlighting a focus on innovation[50] Cash Flow Management - Cash flow from operating activities generated a net amount of CNY 170,292,205.53, significantly higher than CNY 47,353,068.53 in the previous year, marking an increase of 259.5%[62] - The net cash flow from operating activities for Q3 2020 was CNY 144,106,237.85, a significant increase from CNY 49,403,691.39 in Q3 2019, representing a growth of approximately 190%[67] - Cash and cash equivalents at the end of the period stood at CNY 49,812,723.41, compared to CNY 37,849,188.79 at the end of the previous year, indicating an increase of 31.5%[64] Market Strategy - The significant revenue growth was attributed to increased market share in blood purification products and the production of pandemic-related supplies such as masks and disinfectants[22] - The company plans to continue expanding its market presence and product offerings, particularly in the medical technology sector[23] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[52]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥436,650,951.54, representing a 51.22% increase compared to ¥288,745,170.87 in the same period last year[23]. - The net profit attributable to shareholders of the listed company reached ¥44,484,984.73, a significant increase of 160.22% from ¥17,095,154.34 in the previous year[23]. - The net cash flow from operating activities surged to ¥104,287,110.63, marking a 1,139.75% increase compared to ¥8,411,918.15 in the same period last year[23]. - Basic earnings per share rose to ¥0.1693, up 158.87% from ¥0.0654 in the previous year[23]. - Operating profit reached 64.79 million yuan, reflecting a significant year-on-year growth of 228.24%[68]. - The company reported a significant increase in income tax expenses, which rose by 273.31% to ¥9,665,766.73, attributed to increased profits during the reporting period[81]. - The company reported a total operating cost of CNY 377.11 million, which is a 39.1% increase from CNY 271.08 million in the first half of 2019[176]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,150,557,673.20, reflecting a 0.42% increase from ¥1,145,700,357.46 at the end of the previous year[23]. - Total liabilities decreased to CNY 408,892,414.27 from CNY 427,676,260.49, reflecting a reduction of approximately 4.4%[170]. - The company reported a decrease in short-term borrowings to CNY 125,000,000.00 from CNY 132,631,000.00, a decline of approximately 5.5%[169]. - The company's cash and cash equivalents decreased to CNY 73,749,178.77 from CNY 110,900,982.10, representing a decline of approximately 33.5%[168]. - The total liabilities at the end of the reporting period were CNY 309,181,648.04, indicating the company's financial obligations[197]. Market Position and Strategy - The company has successfully transformed from traditional infusion products to providing a complete blood purification solution, becoming one of the few companies in China to do so[28]. - The core business of the company focuses on blood purification products, which are essential for patients with end-stage renal disease, including hemodialysis machines and disposable hollow fiber dialyzers[30]. - The company aims to replace over 90% of imported dialysis machines with domestically produced alternatives, enhancing local manufacturing capabilities[33]. - The company is actively pursuing market expansion opportunities in both domestic and international markets, particularly in the field of blood purification and dialysis products[34]. - The company is focusing on improving operational efficiency and exploring potential mergers and acquisitions to strengthen its market position[191]. Research and Development - The company invested 18.64 million yuan in research and development, which constituted 4.27% of total revenue during the reporting period[75]. - Research and development investment rose to ¥18,637,464.73, marking a 68.03% increase from ¥11,091,454.29 in the previous year, reflecting the company's commitment to enhancing R&D efforts[82]. - The company is currently applying for registration certificates for four medical devices, with all in the normal review stage[76]. - The company has established a global marketing system and a nationwide production base layout, enhancing its operational capabilities[64]. Product Offerings - The company has expanded its product line to include protective products in response to the COVID-19 pandemic, such as disposable medical masks and disinfectants[31]. - The company’s dialysis products include a range of items such as blood purification infusion tubes and dialysis machines, which are essential for treating acute and chronic renal failure patients[34]. - The company’s blood purification infusion tube features a precision drug filter that can filter out insoluble particles ranging from 5-15μm, ensuring infusion safety[37]. - The company has developed a series of self-destructing syringes for vaccine injection, which prevent accidental reuse and cross-infection, enhancing safety for healthcare workers[39]. Shareholder Information - The total number of shares is 262,705,000, with a change in restricted shares from 101,609,700 to 89,955,570[141]. - The largest shareholder, Peng Yixing, holds 24.79% of shares, totaling 65,115,920 shares, with 16,278,980 shares pledged[150]. - The company reported a commitment from major shareholders to not reduce their holdings for three years post-IPO[111]. - Shareholders are required to announce any intended share reductions three trading days in advance[111]. Compliance and Governance - The company has committed to ensuring that no false statements or omissions exist in its disclosure documents[112]. - The company will not provide financial assistance to incentive plan participants for acquiring restricted stock[112]. - The company has established a plan to ensure compliance with relevant laws and regulations regarding share reductions[111]. - The financial report for the first half of 2020 was not audited, indicating a potential area for further scrutiny[166]. Operational Challenges - The company faces risks related to national policy changes, quality control, and market contraction in traditional infusion products[6][9]. - The company reported a significant decrease in traditional infusion product market capacity due to national healthcare reforms, prompting a shift towards innovative product development[102]. - The company plans to continue focusing on quality management to mitigate risks associated with the production of Class III medical devices, which are subject to strict regulatory scrutiny[101].